Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen

NCT01037348 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
65
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis